Literature DB >> 25860852

Treatment of hemorrhagic gastritis by Ankaferd blood stopper versus Omeprazole: experimental randomized rat models.

Hikmetullah Batgi1, Erdem Akbal2, Erdem Koçak3, Ömer Akyürek4, Seyfettin Köklü5, Melahat Dönmez6, Fahri Güneş7.   

Abstract

BACKGROUND: Ankaferd blood stopper (ABS) is a herbal extract that enhances mucosal healing. It has therapeutic potential in the management of external hemorrhage and controlling gastrointestinal bleeding associated with various benign lesions refractory to conventional antihemorrhagic measures. The aim of this experimental study was to assess the effects of ABS on hemorrhagic lesions and compare them with omeprazole.
METHODS: The study was conducted on 30 rats. Rats were divided into five groups: group A (only indomethacin), group B (ABS administration 60 min before indomethacin-induced injury), group C (ABS administration 30 min after indomethacin-induced injury), group D (omeprazole administration 60 min before indomethacin-induced injury), group E (omeprazole administration 30 min after indomethacin-induced injury). Gastric mucosal lesions were produced by indomethacin in all three groups. The effect was studied morphologically 6 h after oral administration of the drug. Subsequently, affected tissue was examined histologically.
RESULTS: Based on the number and the total size of hemorrhagic lesions, the hemorrhagic lesion scores were significantly better in Group C compared to other groups (p < 0.05). The hemorrhagic lesion score of Group B was significantly better than Group D and Group A (p < 0.05). Omeprazole groups (Group D, Group E) did not show significant improvement as indicated by macroscopic scores. There was no significant difference between the groups with respect to microscopic scores.
CONCLUSION: These results indicate that ABS has a potent inhibitory action on indomethacin-induced gastric bleeding and mucosal lesions and it is useful in the treatment of acute gastric mucosal lesions.

Entities:  

Keywords:  Ankaferd blood stopper; Hemorrhagic gastritis; Omeprazole

Mesh:

Substances:

Year:  2015        PMID: 25860852     DOI: 10.1007/s00508-015-0762-2

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  35 in total

Review 1.  Evaluation of hemostatic effects of Ankaferd as an alternative medicine.

Authors:  Yavuz Beyazit; Mevlut Kurt; Murat Kekilli; Hakan Goker; Ibrahim Celalettin Haznedaroglu
Journal:  Altern Med Rev       Date:  2010-12

2.  Ankaferd Blood Stopper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract.

Authors:  M Kurt; S Kacar; I K Onal; M Akdogan; I C Haznedaroglu
Journal:  Endoscopy       Date:  2008-12-17       Impact factor: 10.093

3.  A new practical alternative for tumoural gastrointestinal bleeding: Ankaferd blood stopper.

Authors:  Ersan Ozaslan; Tugrul Purnak; Ayla Yildiz; Ibrahim C Haznedaroglu
Journal:  Dig Liver Dis       Date:  2009-12-11       Impact factor: 4.088

4.  Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis.

Authors:  Aysenur Meric Teker; Arzu Yasemin Korkut; Volkan Kahya; Orhan Gedikli
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-02-13       Impact factor: 2.503

5.  Effectiveness of Ankaferd blood stopper in the topical control of active bleeding due to cutaneous-subcutaneous incisions.

Authors:  Behcet Al; Cuma Yildirim; Murat Cavdar; Suat Zengin; Hasan Buyukaslan; Mehmet E Kalender
Journal:  Saudi Med J       Date:  2009-12       Impact factor: 1.484

6.  Gastric ammonia has a potent ulcerogenic action on the rat stomach.

Authors:  M Murakami; H Saita; S Teramura; H Dekigai; K Asagoe; S Kusaka; T Kita
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

7.  The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model.

Authors:  Ali Kosar; Handan S Cipil; Arif Kaya; Burak Uz; Ibrahim C Haznedaroglu; Hakan Goker; Oktay Ozdemir; Sevil Ercetin; Serafettin Kirazli; Huseyin Cahit Firat
Journal:  Blood Coagul Fibrinolysis       Date:  2009-04       Impact factor: 1.276

8.  Topical application of ankaferd hemostat in a patient with gastroduodenal amyloidosis complicated with gastrointestinal bleeding.

Authors:  Yavuz Beyazit; Fatih Oguz Onder; Serkan Torun; Adnan Tas; Tugrul Purnak; Ilyas Tenlik; Nesrin Turhan
Journal:  Blood Coagul Fibrinolysis       Date:  2013-10       Impact factor: 1.276

9.  Effect of Ankaferd Blood Stopper on air leakage in the lung and prevention of bleeding: an experimental study.

Authors:  Ali Kılıçgün; Necla G Sarıkaş; Tanzer Korkmaz; Ozkan Saydam; Cetin Boran; Güledal Boztaş
Journal:  J Cardiothorac Surg       Date:  2011-02-27       Impact factor: 1.637

10.  Anti-inflammatory efficiency of Ankaferd blood stopper in experimental distal colitis model.

Authors:  Erdem Koçak; Erdem Akbal; Adnan Taş; Seyfettin Köklü; Gökhan Karaca; Murat Can; Bahadir Kösem; Hüseyin Üstün
Journal:  Saudi J Gastroenterol       Date:  2013 May-Jun       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.